Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
Enregistré dans:
Auteur principal: | Xiaoying Zhang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Georg Thieme Verlag KG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/252b3ac718da4cfca5ef207a3cbd1f8d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
par: Yaning Yang, et autres
Publié: (2021) -
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
par: Yen-Hsiang Huang, et autres
Publié: (2021) -
Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
par: Yen-Hsiang Huang, et autres
Publié: (2021) -
The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
par: Motohiro Tamiya, et autres
Publié: (2021) -
Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
par: Haomin Zhang, et autres
Publié: (2021)